Torsten Hoffmann, inventor of the anti-emetic medicine Akynzeo, has been named chief scientific officer at Oryzon Genomics SA which is developing epigenetic-based therapeutics. He succeeds Tamara Maes who is retiring. Dr Hoffmann joins from Taros Chemicals GmbH in Germany. During his more than 23 years in pharma R&D, he has held senior positions at Zealand Pharma A/S and at the Roche Group.
Dr Hoffmann received a PhD in chemistry from ETH Zurich in Switzerland and was a research associate at the Scripps Research Institute in the US.
Oryzon announced the appointment on 2 November 2020
Copyright 2020 Evernow Publishing Ltd